Poly Medicure Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 10 Aug 2026

Company page: Poly Medicure share price, financials & guidance record

Poly Medicure Limited reported a strong Q1 FY27 with consolidated revenue up 30.3% to INR525 crores and standalone EBITDA margin at 28%, surpassing guidance. The company launched its PolyMed 3.0 strategy aiming to double revenue by FY30 through organic and inorganic expansion, focusing on high-technology segments. While Europe showed strong recovery, the Middle East faced significant de-growth due to geopolitical issues and supply chain disruptions. The renal business also saw a decline amidst pricing pressure.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 30.3%, net profit down 8.6% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	420	424	441	403	444 +6%	494 +17%	535 +21%	525 +30%
Expenses	305	310	321	298	329	382	424	400
EBITDA	115	114	119	106	115 +0%	111 −3%	110 −8%	125 +18%
Margin	27%	27%	27%	26%	26%	23%	21%	24%
Other income	27	24	27	43	35	21	19	35
Interest	3	3	2	3	3	6	6	6
Depreciation	21	21	21	23	25	29	38	36
Profit before tax	118	113	123	123	122 +3%	98 −13%	85 −31%	117 −5%
Tax rate	26%	25%	25%	24%	25%	27%	24%	27%
Net profit	87	85	92	93	92 +6%	71 −16%	65 −29%	85 −9%
EPS	8.63	8.41	9.06	9.19	9.06	7.00	6.54	8.49

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls